David Lam

David Lam

Auto-generated profile, based on publicly available information

David Lam

Icahn School of Medicine at Mt. Sinai New York New York USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2022 in American Journal of Nephrology
Verified
Journal Article
Open access
PDF file
DLDavid Lam
David Lam
Girish N. NadkarniGirish N. Nadkarni
Girish N. Nadkarni
GMGohar Mosoyan
Gohar Mosoyan
Bruce NealBruce Neal
Bruce Neal
KMKenneth W. Mahaffey
Kenneth W. Mahaffey
SCSteven G. Coca
Steven G. Coca
Introduction: KidneyIntelX is a composite risk score, incorporating biomarkers and clinical variables for predicting progression of diabetic kidney disease (DKD). The utility of this score in the context of sodium glucose co-transporter 2 inhibitors and how changes in the risk score associate with future kidney outcomes are unknown. Methods: We measured soluble tumor necrosis factor receptor (TNFR)-1, soluble TNFR-2, and kidney injury molecule 1 on banked samples from CANagliflozin cardioVascular Assessment Study (CANVAS) trial participants with baseline DKD (estimated glomerular filtration rate [eGFR] 30–59 mL/min/1.73 m2 or urine albumin-to-creatinine ratio [UACR] ≥30 mg/g) and generated KidneyIntelX risk scores at baseline and years 1, 3, and 6. We assessed the association of baseline and changes in KidneyIntelX with subsequent DKD progression (composite outcome of an eGFR decline of ≥5 mL/min/year [using the 6-week eGFR as the baseline in the canagliflozin group], ≥40% sustained decline in the eGFR, or kidney failure). Results: We included 1,325 CANVAS participants with concurrent DKD and available baseline plasma samples (mean eGFR 65 mL/min/1.73 m2 and median UACR 56 mg/g). During a mean follow-up of 5.6 years, 131 participants (9.9%) experienced the composite kidney outcome. Using risk cutoffs from prior validation studies, KidneyIntelX stratified patients to low- (42%), intermediate- (44%), and high-risk (15%) strata with cumulative incidence for the outcome of 3%, 11%, and 26% (risk ratio 8.4; 95% confidence interval [CI]: 5.0, 14.2) for the high-risk versus low-risk groups. The differences in eGFR slopes for canagliflozin versus placebo were 0.66, 1.52, and 2.16 mL/min/1.73 m2 in low, intermediate, and high KidneyIntelX risk strata, respectively. KidneyIntelX risk scores declined by 5.4% (95% CI: −6.9, −3.9) in the canagliflozin arm at year 1 versus an increase of 6.3% (95% CI: 3.8, 8.7) in the placebo arm (p < 0.001). Changes in the KidneyIntelX score at year 1 were associated with future risk of the composite outcome (odds ratio per 10 unit decrease 0.80; 95% CI: 0.77, 0.83; p < 0.001) after accounting for the treatment arm, without evidence of effect modification by the baseline KidneyIntelX risk stratum or by the treatment arm. Conclusions: KidneyIntelX successfully risk-stratified a large multinational external cohort for progression of DKD, and greater numerical differences in the eGFR slope for canagliflozin versus placebo were observed in those with higher baseline KidneyIntelX scores. Canagliflozin treatment reduced KidneyIntelX risk scores over time and changes in the KidneyIntelX score from baseline to 1 year associated with future risk of DKD progression, independent of the baseline risk score and treatment arm.

29 April 2021 in Kidney360
Verified
Journal Article
Closed access
PDF file
DLDavid Lam
David Lam
ASAisha Shaikh
Aisha Shaikh
This is an Early Access article. Please select the PDF button, above, to view it.

6 September 2021 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
RGRodolfo J. Galindo
Rodolfo J. Galindo
FPFrancisco J. Pasquel
Francisco J. Pasquel
PVPriyathama Vellanki
Priyathama Vellanki
RARZ Alicic
RZ Alicic
DLDavid W. Lam
David W. Lam
GUGuillermo E. Umpierrez
Guillermo E. Umpierrez

13 April 2023 in American Journal of Ophthalmology
Verified
Journal Article
Open access
BNB. Natterson-Horowitz
B. Natterson-Horowitz
BMBret A. Moore
Bret A. Moore
ARAlbert C. Reynolds
Albert C. Reynolds
LELuisa Espericueta
Luisa Espericueta
JHJason J. Head
Jason J. Head
DHD Hunter
D Hunter

28 June 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
DLDavid Lam
David Lam
BFBarry I. Freedman
Barry I. Freedman
JTJoji Tokita
Joji Tokita
FFFergus Fleming
Fergus Fleming
MSMayte Suarez‐Farinas
Mayte Suarez‐Farinas
MDMichael J. Donovan
Michael J. Donovan

6 August 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
TYTae Won Yi
Tae Won Yi
SSSlaven Sikirica
Slaven Sikirica
SRSaketh Rompicherla
Saketh Rompicherla
STSusan Thapa
Susan Thapa
MDMichael Davies
Michael Davies
DCDavid Z. I. Cherney
David Z. I. Cherney